Romidepsin
- Generic Name
- Romidepsin
- Brand Names
- Istodax
- Drug Type
- Small Molecule
- Chemical Formula
- C24H36N4O6S2
- CAS Number
- 128517-07-7
- Unique Ingredient Identifier
- CX3T89XQBK
- Background
Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
- Indication
用于在已接受至少1次既往全身治疗的患者中皮肤T-细胞淋巴瘤的治疗(CTCL)。
- Associated Conditions
- Cutaneous T-Cell Lymphoma (CTCL)
- Associated Therapies
- -
Ph1 Volasertib Plus Romidepsin in R/R PTCL and CTCL
- First Posted Date
- 2016-05-02
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- Anne Beaven, MD
- Registration Number
- NCT02757248
Study to Evaluate the Safety and Effect of HIVconsv Vaccines in Combination With Histone Deacetylase Inhibitor Romidepsin on the Viral Rebound Kinetic After Treatment Interruption in Early Treated HIV-1 Infected Individuals
- First Posted Date
- 2015-11-30
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- IrsiCaixa
- Target Recruit Count
- 15
- Registration Number
- NCT02616874
- Locations
- 🇪🇸
Clinic Hospital, Barcelona, Spain
🇪🇸Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain
A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-11-30
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 16
- Registration Number
- NCT02616965
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸University of Pennsylvania, Perelman Center, Philadelphia, Pennsylvania, United States
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
- First Posted Date
- 2015-07-31
- Last Posted Date
- 2024-10-29
- Target Recruit Count
- 23
- Registration Number
- NCT02512497
- Locations
- 🇺🇸
The Ohio State University Cancer Center, Columbus, Ohio, United States
A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-07-30
- Last Posted Date
- 2022-03-22
- Target Recruit Count
- 27
- Registration Number
- NCT02512172
- Locations
- 🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
- Conditions
- Interventions
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2023-04-27
- Lead Sponsor
- Priyanka Sharma
- Target Recruit Count
- 51
- Registration Number
- NCT02393794
- Locations
- 🇺🇸
University of Kansas Cancer Center - Westwood, Westwood, Kansas, United States
🇺🇸University of Kansas Cancer Center - West, Kansas City, Kansas, United States
🇺🇸University of Kansas Cancer Center - Overland Park, Overland Park, Kansas, United States
Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT02341014
- Locations
- 🇺🇸
Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Westchester, Harrison, New York, United States
Long-term Use of Romidepsin in Patients With CTCL
- First Posted Date
- 2014-11-20
- Last Posted Date
- 2016-03-11
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 47
- Registration Number
- NCT02296398
- Locations
- 🇺🇸
Northwestern University Dermatology Department, Chicago, Illinois, United States
Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueNodal Marginal Zone B-cell LymphomaRecurrent Adult Burkitt LymphomaRecurrent Adult Lymphoblastic LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent Small Lymphocytic LymphomaB-cell Adult Acute Lymphoblastic LeukemiaRecurrent Grade 3 Follicular LymphomaSmall Intestine LymphomaTesticular Lymphoma
- Interventions
- First Posted Date
- 2014-11-02
- Last Posted Date
- 2016-08-11
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT02281279
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
- Conditions
- Adult Nasal Type Extranodal NK/T-cell LymphomaHepatosplenic T-cell LymphomaPeripheral T-cell LymphomaStage II Cutaneous T-cell Non-Hodgkin LymphomaStage IIIB Mycosis Fungoides/Sezary SyndromeStage IVB Mycosis Fungoides/Sezary SyndromeAnaplastic Large Cell LymphomaStage I Cutaneous T-cell Non-Hodgkin LymphomaStage IA Mycosis Fungoides/Sezary SyndromeStage IVA Mycosis Fungoides/Sezary Syndrome
- Interventions
- First Posted Date
- 2014-09-05
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 30
- Registration Number
- NCT02232516
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Weill Cornell Medicine, New York, New York, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.